ANI Q2 2026 earnings: Cortrophin drives 25.9% revenue growth

ANI Pharmaceuticals (NASDAQ: ANIP) reported Q2 2026 net revenue of $266.0 million, up 25.9% from $211.4 million a year earlier, while diluted GAAP EPS increased to $1.05 from $0.36. Net income available to common shareholders rose to $24.7 million, and adjusted non-GAAP EBITDA grew 32.4% to $71.6 million, led primarily by Cortrophin Gel despite a lower gross margin.

Core financial results

The results, released on August 7, cover the quarter ended June 30, 2026. Revenue growth translated into higher gross profit, operating income and adjusted EBITDA, although a less favorable product mix reduced GAAP gross margin by 2.3 percentage points.

Operating margin was approximately 15.2%, compared with 6.6% a year earlier. The improvement reflects higher gross profit dollars, lower research and development expense, lower depreciation and amortization, and a more favorable contingent consideration adjustment, partly offset by increased selling, general and administrative expense.

Business and segment performance

Cortrophin Gel remained ANI’s principal growth driver. Generics also contributed, while ILUVIEN and the Brands portfolio declined for different reasons.

Cortrophin’s increase was driven mainly by higher volume in existing specialties, including nephrology, neurology, ophthalmology, pulmonology and rheumatology. The sales-force expansion targeting podiatrists and primary care physicians treating acute gouty arthritis became fully operational only at the end of June, so existing specialties—not the new gout initiative—were the main source of Q2 growth.

ILUVIEN revenue declined because of the timing of shipments in certain international markets. ANI recorded no YUTIQ sales in the quarter as U.S. promotional efforts transitioned to ILUVIEN, which has a combined label covering diabetic macular edema and chronic non-infectious uveitis affecting the posterior segment.

Generic pharmaceutical product revenue benefited from new launches, a partnered generic introduced in Q3 2025, and what the company described as commercial and operational outperformance. ANI launched 12 generic products during the first half and remained on track for at least 15 launches in 2026.

Brand royalties and other revenue included $9.7 million of royalties on pitolisant-based products and $8.0 million tied to development work under the Harmony Agreement. ANI expects to recognize another $2.0 million of development milestone revenue when the remaining work is completed in Q3, while continuing to receive low-single-digit royalties on relevant sales.

Revenue mix compressed gross margin, but operating income still expanded

GAAP gross margin declined to 62.4% from 64.7%, while non-GAAP gross margin fell to 62.6% from 64.9%. ANI attributed the contraction primarily to increased sales of royalty-bearing products, including Cortrophin Gel and the partnered generic launched in Q3 2025, as well as the absence of prior-year Prucalopride revenue. Harmony Agreement revenue partially offset these pressures.

Despite the lower percentage margin, GAAP gross profit increased by approximately $29.1 million because of the larger revenue base. GAAP selling, general and administrative expense rose 12.1% to $91.7 million, including initial marketing and recruitment costs for the Rare Disease sales-force expansion. Non-GAAP SG&A increased 20.2% to $80.7 million.

GAAP research and development expense declined 10.8% to $14.7 million due to project timing. Depreciation and amortization also decreased to $19.6 million from $23.3 million. Together, these movements helped operating income grow faster than revenue even as gross margin narrowed.

Cash flow and balance sheet

ANI generated $115.0 million of operating cash flow during the first six months of 2026. This is a year-to-date figure rather than Q2 cash flow.

At June 30, unrestricted cash and cash equivalents were $360.2 million, up approximately $74.6 million from December 31, 2025. The company also reported $274.5 million of net accounts receivable, $143.1 million of inventory and $620.9 million in principal value of outstanding debt, including senior convertible notes.

ANI’s board authorized a program on May 8 allowing the company to repurchase up to $100.0 million of common stock through May 2029. The release did not specify how much, if any, had been repurchased under that authorization.

Full-year 2026 guidance

ANI reaffirmed its consolidated revenue, adjusted EBITDA and adjusted EPS ranges, but lowered its Cortrophin Gel revenue outlook. The revised Cortrophin range still implies 50% to 55% growth from 2025, although both ends are below the previous forecast.

The company also expects a full-year adjusted non-GAAP gross margin of 59.9% to 60.9%. Maintaining the total-company outlook while lowering the Cortrophin range increases the importance of execution across Generics, ILUVIEN, Brands and royalty-related revenue during the second half.

Management’s view

Management said the early demand indicators from the new gout initiative were positive. More than 95% of the expanded sales representatives had generated multiple new patient cases, and more than one-third of prescribers had initiated at least two cases. Demand was described as balanced between podiatrists and primary care physicians.

The company estimates that this expansion addresses approximately 285,000 patients. Management also reported continued momentum in Cortrophin’s existing specialties in July, but the initiative remains at an early stage and its contribution must be considered alongside the reduced full-year product guidance.

For ILUVIEN, ANI plans to present detailed results and additional analyses from its Phase 4 SYNCHRONICITY trial at a medical conference in Q4 2026.

Recent insider transactions

The supplied insider data showed 216,780 shares categorized as purchases across 17 transactions and 141,716 shares categorized as sales across 26 transactions during the past six months, resulting in a reported net acquisition of 75,064 shares. These aggregate categories can include awards and derivative exercises and therefore should not automatically be interpreted as open-market buying.

The 10 most recent reported transactions were concentrated in sales, derivative exercises and one stock award.

The transaction data alone does not establish insiders’ views about ANI’s future operating performance.

Risks investors should monitor

• Cortrophin execution: Cortrophin grew 43.5% in Q2, but ANI lowered its full-year product revenue guidance. Converting early gout patient cases into sustained revenue is therefore an important second-half variable.
• Product-mix pressure: Higher sales of royalty-bearing products supported revenue but reduced gross margin. Continued growth in these products could keep percentage margins below the prior-year level.
• Cost of the gout expansion: SG&A increased as ANI recruited and marketed for its expanded Rare Disease team. The pace of new patient starts will determine how effectively those additional costs translate into revenue growth.
• ILUVIEN and Brands volatility: International shipment timing reduced ILUVIEN revenue, while normalization in demand weighed on Brands. Continued volatility could affect the mix needed to support consolidated guidance.
• Milestone revenue comparability: Q2 included $8.0 million of Harmony development milestone revenue, with another $2.0 million expected in Q3. The ongoing royalty stream remains, but development milestone revenue is tied to completion of specified work.

Summary

ANI’s Q2 2026 growth was led by Cortrophin Gel, with additional contributions from generic products and the Harmony Agreement. Higher revenue and controlled growth in several operating costs produced substantial operating-income and EBITDA expansion despite lower gross margin. The main issues for the second half are whether the gout sales-force expansion can support Cortrophin’s revised outlook and whether the rest of the portfolio can help ANI deliver its unchanged consolidated guidance.